<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119500">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116270</url>
  </required_header>
  <id_info>
    <org_study_id>IRIS API/2012/28</org_study_id>
    <nct_id>NCT02116270</nct_id>
  </id_info>
  <brief_title>Accelerated Immunosenescence and Chronic Kidney Disease</brief_title>
  <acronym>IRIS</acronym>
  <official_title>Accelerated Immunosenescence and Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the impact of renal function and dialysis techniques
      on the percentage of senescent T lymphocytes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immunosenescence is a complex and profound remodeling of the immune system during life.
      It is mainly due to thymic involution and repeated antigenic stimulation. Kidney disease is
      associated with a decrease in adaptive immunity as evidenced by the decrease in vaccine
      response and increased susceptibility to infections, similar to those observed in the
      elderly population.

      However, data on aging of the immune system in chronic kidney disease remains incomplete.
      Furthermore, the determinants of immunosenescence are not also not known. It is possible
      that &quot;uremic&quot; factors help explain the phenotypic and functional changes of lymphocytes, as
      antigenic stimuli associated with repeated bio-compatible materials used in dialysis
      contact.

      The purpose of this study is to describe the phenotypes of the immune system of renal and
      analyze the determinants of these changes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Percentage of Cluster of Differentiation (CD) 4/8+ CD 57+ CD 28- lymphocytes (senescent lymphocytes)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure is the percentage of CD 4/8+ CD 57+ CD 28- lymphocytes by flow cytometry. The technique used is a 6 colors surface labelling of T lymphocytes to study the T cell senescent population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Telomerase Activity of T lymphocytes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The telomerase activity of T lymphocytes is assessed by a method of Polymerase chain reaction (PCR)-ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of phospho-histone 2AX (gH2AX) in peripheral blood T lymphocytes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This level is obtained by flow cytometry after permeabilization and labelling of Peripheral Blood Mononuclear Cells (PBMC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Recent Thymic Emigrants (RTE) in peripheral blood T lymphocytes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>RTE T cells will be defined by flow cytometry, according to co-expression of CD 4, CD 8,CD 31 and CD 45RA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell receptor excision circle (TREC) level in PBMC.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>TRECs study is based on a technique of quantitative PCR using DNA extracted from PBMC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telomere length in T lymphocytes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study of telomere length is performed after extraction of DNA from isolated T cells. The length is determined by a quantitative PCR technique relative to a reference gene.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Severe renal failure</arm_group_label>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient able to understand the reason of the study

          -  Patient not opposed to the conservation of biological samples for scientific research

        Exclusion Criteria:

          -  Patient suffering from psychotic illness

          -  Any history of immunosuppressive therapy (except steroids up to 5mg/day)

          -  History of cancer (except skin cancer) or treated hematological malignancy

          -  Infectious episode required hospitalization not older 3 months

          -  Hepatitis B or C infection

          -  HIV infection, active or inactive

          -  For dialysis patients: renal failure on dialysis for less than 3 months and/or have
             benefited from two techniques for renal replacement therapy in the last 5 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamal BAMOULID, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamal BAMOULID, Doctor</last_name>
    <phone>+33381218197</phone>
    <email>jbamoulid@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid TISSOT</last_name>
    <phone>+33381218427</phone>
    <email>itissot@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de néphrologie, CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal BAMOULID, Doctor</last_name>
      <phone>+33381218197</phone>
      <email>jbamoulid@chu-besancon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid TISSOT</last_name>
      <phone>+33381218427</phone>
      <email>itissot@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jamal BAMOULID, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile COURIVAUD, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier DUCLOUX, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc CHALOPIN, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François KLEINCLAUSS, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas CREPIN, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline ROUBIOU, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Failure</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Biological Aging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
